Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and efficacy of Omnitarg (Pertuzumab) on
cancerous lesions in men with castration-resistant (hormone-refractory) prostate cancer.